Sagimet Biosciences presented a subset analysis of the FASCINATE-2 P2 trial of denifanstat in MASH patients at The Liver Meeting showing improved fibrosis based on an AI pathology analysis method

blonca9
Nov 18, 2024
1 min read

CEO David Happel describes how this fatty acid synthase (FASN) inhibitor works, and the AI method suggesting the therapy is having an impact on liver fibrosis. Plus, plans for initiating a phase 3 study.

Recent Posts

See All

Dianthus Therapeutics made waves in September when it announced data from its lead program claseprubart in generalized Myasthenia Gravis - CEO Marino Garcia walks us through the program and data

OrbiMed's Carl Gordon shares his take on biotech's 2025 and what could be ahead for the sector in 2026

CREATE Medicines' platform allows it to program CARs into multiple immune cell types inside the body, and is redosable. While this includes CAR-T, they believe that "in vivo is more than T-cells."

Sagimet Biosciences presented a subset analysis of the FASCINATE-2 P2 trial of denifanstat in MASH patients at The Liver Meeting showing improved fibrosis based on an AI pathology analysis method

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight